Abstract
Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Central Nervous System Agents in Medicinal Chemistry
Title:Genetics in Neural Toxicities of Drugs
Volume: 12 Issue: 4
Author(s): Da-Yong Lu, Ting-Ren Lu and Peng-Peng Zhu
Affiliation:
Keywords: Side effects of drug, human genome, neural toxicity, antidepressant, antibiotics, genetics, drug develop, drug safety, medicinal chemistry, genomic study, pharmacogenomics, mental toxicity
Abstract: Adverse side effects or toxicities of a drug were previously regarded as a manifestation of drug’s own characterizations, such as the chemical structure and property of a drug. More recently, increasing experimental or clinical data and modern ideas suggest that human’s genetic factors also play indispensable roles in resulting neural side effects of a drug, especially in antidepressant-induced suicide and antibiotics-induced hearing loss. However, there are many questions and technological obstacles (including high costs and limited samples) in these kinds of researches and this makes genetic study of drug toxicities in its initial stage. In this review, we in depth address and analysis of this matter from some new perspectives and propose some new initiatives to improve this type of researches in future. It is also highly needed to expedite the translation of these pharmacogenetic concepts from bench to bedside.
Export Options
About this article
Cite this article as:
Lu Da-Yong, Lu Ting-Ren and Zhu Peng-Peng, Genetics in Neural Toxicities of Drugs, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (4) . https://dx.doi.org/10.2174/187152412803760591
DOI https://dx.doi.org/10.2174/187152412803760591 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adolescent Pornography Use: A Systematic Literature Review of Research Trends 2000-2017
Current Psychiatry Reviews Editorial (Hot Topic: Neuroprotection Against Stroke and CNS Injury: New Mechanisms, Targets, and Controversies)
CNS & Neurological Disorders - Drug Targets Leptin, Estrogens and Cancer
Mini-Reviews in Medicinal Chemistry Conference Report
CNS & Neurological Disorders - Drug Targets Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor
Current Clinical Pharmacology The Protective Role of Heme Oxygenase-1 in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Mast Cell – Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications
CNS & Neurological Disorders - Drug Targets Imaging as a Strategy for Premortem Diagnosis and Staging of Tauopathies
Current Alzheimer Research Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design The Role of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke: From Laboratory to Clinics
Current Vascular Pharmacology Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea)
Current Pharmaceutical Design Botulinum Toxin a in Prostate Disease: A Venom from Bench to Bed-Side
Current Drug Delivery Pregabalin Dependence: A Case Report
Current Drug Safety Dietary Flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy
Current Neuropharmacology Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?
Current Pharmaceutical Design Dysfunctional Immune-Mediated Inflammation in Rheumatoid Arthritis Dictates that Development of Anti-Rheumatic Disease Drugs Target Multiple Intracellular Signaling Pathways
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer
Current Drug Targets Zebrafish: Predictive Model for Targeted Cancer Therapeutics from Nature
Current Cancer Drug Targets